Close Asset Management’s Summit Therapeutics SMMT Stock Holding History

Close Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-800	Closed	-$5K	–	218
2021 Q1	$5K	Buy	+800	New	+$5.16K	﹤0.01%	201

Other funds holding SMMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Close Asset Management's SMMT Position: Q2 2021 in Review

Close Asset Management sold out of Summit Therapeutics (SMMT) in Q2 2021, closing a stake of 800 shares — an estimated $5K sold.

Close Asset Management first reported a position in SMMT in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 58 funds tracked by Wall St. Rank hold SMMT as of Q2 2021.

Close Asset Management reported no remaining Summit Therapeutics position as of Q2 2021 after selling out during the quarter.
Close Asset Management sold 800 Summit Therapeutics shares in Q2 2021, an estimated $5K.
Close Asset Management first reported a position in Summit Therapeutics in Q1 2021 and held it in 1 quarter.
Close Asset Management's Summit Therapeutics position peaked at $5K in Q1 2021.
58 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2021.

Based on Close Asset Management's 13F filing for Q2 2021, filed 27 Jul 2021.